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laxatives, wheat bran and intestinal antibiotics, the 
deoxycholate pool is contracted and CSI falls (4,5). Thus 
maneuvers that alter colonic transit affect the DCA pool 
size and CSI. The observation that women of child- 
bearing age also have prolonged transit times and 
greater tendency toward constipation is intriguing in 
light of the observations that this population group is at 
high risk for cholesterol gallstones (6). 
An increased percentage of DCA in the bile acid pool 
has been observed in several studies examining gallstone 
subjects (5). The mechanism whereby DCA increases 
CSI is not entirely certain, although studies indicate 
that excretion of this bile acid causes a greater increase 
in cholesterol output than does an increase in chenode- 
oxycholic acid (CDCA). This difference is explained by 
the fact that DCA is more hydrophobic; this quality may 
cause a greater solubilization of bile canalicular choles- 
terol. An additional mechanism whereby DCA would 
increase CSI is that an increase in DCA pool size is 
generally paralleled by a decrease in the CDCA pool (5). 
Because CDCA has the strongest inhibitory effect on 
cholesterol output, a change in the ratio of DCA to CDCA 
may have significant effects on CSI. In addition to these 
mechanisms, there appears to be a direct correlation 
between the rate of biliary excretion of DCA and 
arachidonic acid content of human biliary lecithin (1). 
Increases in this lipid fraction might enhance prosta- 
glandin synthesis by the gallbladder mucosa. Increased 
prostaglandin levels would increase mucus secretion by 
the gallbladder epithelium, thereby providing a more 
favorable framework for cholesterol nucleation (1). 
Thus colonic factors that increase DCA pool size may 
enhance cholesterol gallstone formation by several 
mechanisms. 
Should we now add prolonged WGTT to the well- 
known risk factors for cholesterol gallstones (i.e., 
obesity, female sex, weight-reduction diets, hypertriglyc- 
eridemia and estrogens)? Certainly at this point it is 
difficult to do so. Krevsky et al. (7), using colonic transit 
scintigraphy, noted a lack of correlation between the 
number of bowel movements and the movement of feces 
through the colon. They suggest that studies counting 
the number of bowel movements or quantitating 
markers may not accurately reflect colonic transit. 
Improved methodologies that allow investigation to 
correlate colonic transit time with biliary bile acid and 
lipid composition would help answer this question. 
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ABSTRACT 
Objective: To determine clinical and economic con- 
sequences of alternative vaccination strategies for 
preventing hepatitis B virus infection (HBV). 
Methods: Decision analysis was used to evaluate 
costs, outcomes, and cost-effectiveness of three HBV 
management strategies (“no vaccination,” “universal 
vaccination,” and “screen and vaccinate”) in four 
populations (newborns, 10-year-old adolescents, a 
high-risk adult population, and the general adult U.S. 
population). Information on HBV incidence and prev- 
alence, clinical course, and management of acute 
illness and chronic sequelae was obtained from the 
literature and a panel of experts. Actual payments 
(costs) were obtained from Blue CrossiBlue Shield and 
local pharmacies. Incremental cost-effectiveness was 
calculated from the perspective of the payer of medical 
care and subjected to sensitivity analysis. 
Results: Vaccination (with or without screening) 
prevents more disease at somewhat increased cost 
than no vaccination for the neonatal, adolescent, and 
adult populations. Vaccination (with or without 
screening) is a dominant strategy in adult high-risk 
populations (lower cost and greater benefit than no 
vaccination). Optimal cost-effectiveness, with non- 
monetary benefits not discounted, results if all 
pregnant women are screened for active HBV in- 
fection, and HBV vaccine and hepatitis B immune 
globulin are administered to babies born to mothers 
with positive screening tests. Then HBV vaccine is 
administered to all children at age 10 and again 10 
years later (incremental cost-per-year-of-life-saved rel- 
ative to the “no vaccination” strategy is $375). A 
strategy of universal newborn vaccination alone leads 
to an incremental cost-per-year-of-life saved of $3332. 
If adolescents are vaccinated at age 10, incremental 
cost-per-year-of-life saved is $13,938; for the general 
adult population, the incremental cost-per-year-of-life 
saved of universal vaccination is $54,524. Discounting 
benefits will increase cost-per-year-of-life saved 7 to 12 
times for all strategies. 
Conclusions: HBV vaccine is most cost-effective 
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when a strategy of screening newborns is combined 
with routine administration to 10-year-old children. 
The means to achieve substantial improvements in the 
health of the public in a cost-effective fashion are now 
available and should be pursued aggressively. 
COMMENTS 
HBV is the world’s most common blood-borne viral 
infection, responsible for substantial morbidity and 
mortality. It is estimated that each year 4,000 to 5,000 
persons in the United States die of HBV-related liver 
diseases, which include HCC. Despite the availability of 
an efficacious HBV vaccine for the past decade, the 
incidence of HBV infection has increased by 37%. 
Various vaccination strategies have been available for 
different risk groups defined by occupation, medical 
conditions and lifestyle, but compliance has been poor. 
Although one can understand the reasons underlying 
the poor vaccination rate among those persons in 
high-risk groups without routine access to preventive 
medical care, it is difficult to understand the poor 
vaccination rate for high-risk health-care professionals, 
of whom fewer than 50% complete a full series. A further 
problem complicating the control of HBV infection is 
that 30% of patients with acute HBV have no acknowl- 
edged risk factors. For these reasons groups such as the 
American Academy of Pediatrics, the Centers for 
Disease Control and Prevention and the American 
Academy of Family Practice now recommend universal 
vaccination of all infants. Unfortunately, this recom- 
mendation has met with skepticism amongst many 
primary-care providers who must administer yet an- 
other set of routine baby shots. The reasons for this 
reluctance include the facts that many pediatricians 
have not seen a case of HBV infection in their practice 
and that most pediatricians do not see the effects of HBV 
in children because most childhood infections are 
asymptomatic. Furthermore, some pediatricians feel 
that it is unlikely that many of the children they see in 
their private practices will eventually fall into a group at 
high risk for HBV infection as adults. Despite these 
rationalizations approximately five times as many 
deaths per year are attributed to HBV than to Haemo- 
philus influenzae type B, and yet H. influenzae type B 
immunizations have received recent widespread accep- 
tance by primary care physicians. Thus this excellent 
study yields important new information on both the 
cost-effectiveness and the improvement in public health 
expected with several different HBV vaccination strat- 
egies. 
This paper expands on the previous efforts of Mulley 
et al., who examined the cost-effectiveness of the HBV 
vaccine more than 10 years ago. However, as the authors 
point out, in the past 10 years the incidence of HBV 
infection has increased and the cost of the recombinant 
vaccine has greatly decreased. Given these facts it is not 
surprising that the HBV vaccination program under 
study is more cost-effective than the suggested programs 
of 10 years ago. The study under comment was based on 
30 years of follow-up, with an initial three-shot series 
and booster vaccinations every 10 years. Also included 
were the latest data on the efficacy and cost ($225 for 
adults and $160 for children) of the new recombinant 
vaccine. Although the study took into account patient 
compliance for all three shots in the initial vaccination 
series and boosters, these investigators chose to ignore 
the program costs necessary to ensure a high level of 
vaccine compliance. As many communities are discov- 
ering, it can not only be very difficult but also very 
expensive to improve on the dismal vaccination rates in 
some areas of the country where childhood immuni- 
zation rates are less than 50%. These costs may have 
particular relevance to HBV vaccination programs; a 
disproportionate number of these unimmunized chil- 
dren are likely to be at high risk of HBV infection as 
adults. The decision-making tree in this paper also took 
into account many of the variables in HBV infection, 
through review of the literature or on the advice of an 
expert panel. These included the sensitivity and speci- 
ficity of HBsAg screening; the incidence of acute in- 
fection in high-risk groups and the general adult 
population, adolescents, and newborns; the types of 
acute infection, from subclinical to fulminant; and the 
chronic sequelae of fulminant and nonfulminant acute 
infection. The authors then examined the costs of 
medical management of acute HBV infection and its 
sequelae. The treatment of chronic HBV infection 
included the use of interferon and liver transplantation. 
The study examined only direct medical costs. Indirect 
medical costs such as travel expenses to receive medical 
care and other indirect nonmedical costs such as time off 
work were not included in the analysis. Other authors 
have estimated nonmedical costs to be 10 times the 
direct medical costs. Costs were presented in two 
formats: either undiscounted or discounted at 5% per 
year. 
The authors examined several vaccination strategies, 
including a “mixed strategy” of screening all pregnant 
women and vaccinating neonates born to infected 
mothers and vaccinating all adolescents at age 10 or as 
they become sexually active. The currently recom- 
mended strategy of vaccinating all newborns and five 
other strategies were also examined. These included 
vaccinating all adolescents, screening and vaccinating 
HBsAg-negative adults in the general population or 
high-risk adults or simply vaccinating all adults or all 
high-risk adults. All the vaccination strategies were 
compared with a no-vaccination strategy. The mixed 
strategy of screening and then vaccinating high-risk 
newborns and vaccinating all adolescents was the most 
cost-effective ($375 per year of life saved). The recom- 
mended strategy of vaccinating all newborns was ap- 
proximately 10 times more expensive (about $3,200). 
Although neither of these strategies save a health care 
system money, they are both cost-effective compared 
with other medical treatments such Pneumococcus 
vaccination for adults older than 65 yr ($6,000) or kidney 
transplant ($7,500). The authors therefore suggest that 
the a mixed strategy be adopted. As is pointed out in the 
accompanying editorial it is, however, a formidable task 
to reach all 10-yr-olds for an expensive vaccine that 
requires three painful injections. Most pediatricians and 
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internists will likely welcome the opportunity to practice 
more preventive medicine with adolescents who will 
need to make more routine office visits for their 
vaccinations, as is the current practice with preschool 
children. Nevertheless, physicians and public policy 
makers, including local school boards, must be con- 
vinced of the benefits of universal HBV vaccination for 
any vaccination strategy to be effective. New school- 
immunization policies that would require proof of 
vaccination on entry to junior high or middle schools 
would help immeasurably. Many school districts have 
already adopted a policy requiring booster injection of 
the mumps/measles/rubella (MMR) vaccine to prevent 
measles outbreaks similar to the ones seen recently in 
many communities. These same districts could also 
require HBV vaccination. Revaccination of children 
after another 10-yr cycle, at 20 yr of age, is much more 
problematic, although it is hoped that the duration of 
the protection against HBV infection lasts longer than 
10 yr. 
An important feature of decision-making analysis 
involves testing of the many variables that inevitably 
involve uncertainties associated with trying to predict 
future events. Therefore the authors examined best-case 
and worst-case scenarios. A worst-case scenario for the 
vaccine program included low rate of vaccine efficacy and 
low incidence of costly sequelae to HBV infection, 
whereas in the best-case scenario the vaccine was 
presumed to be very effective and the incidence of costly 
sequelae of HBV infection also very high. The differ- 
ences in cost per year of life saved between the best-case 
and worst-case scenarios varied only twofold, still 
suggesting that HBV vaccine programs would be cost- 
effective compared with other medical treatments. As 
expected, the cost of implementing a vaccine program 
was also sensitive to the cost of the vaccine. It was 
estimated in a best-case scenario that the cost of a single 
dose of HBV vaccine (including administration) would 
have to be about $10 to $15 for the vaccine program to 
break even with a no-vaccination policy. 
In summary, we agree with the authors of the article 
and the accompanying editorial that a universal vacci- 
nation program should be implemented. For any 
program to be effective, however, it will require the full 
support of the medical community and an educated 
public. Moreover, because the benefits of this program 
will not be seen for many years it is necessary to 
vigorously continue with efforts to vaccinate persons in 
high-risk groups, especially sexually active adults. 
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COMMENTATOR’S ABSTRACT 
In the study reported by Wetterau et al., a recently 
characterized heterodimeric protein called mi- 
crosomal triglyceride transfer protein was unde- 
tectable on immunoblotting of samples from intestinal 
biopsies of human subjects with the genetic disorder 
abetalipoproteinemia. With only one fourth to one fifth 
the soluble proteins of homogenized intestinal biopsy 
specimens of normal human subjects and patients with 
different fat-absorption defects, the 88-kD subunit of 
microsomal triglyceride transfer protein was clearly 
detectable. Protein disulfide isomerase, the 55-kD 
subunit of microsomal triglyceride transfer protein, 
was present in tissue of all subjects tested, including 
those with abetalipoproteinemia. Consistent results 
were obtained with an in uitro assay that mea- 
sures triglyceride transfer between phospholipid 
membranes: triglyceride transfer continued at con- 
stant rates for more than 1 hr in samples from biopsies 
in normal human subjects, whereas no measurable 
triglyceride transfer was detected in the same material 
from abetalipoproteinemia patients. The apparent ab- 
sence of the 88-kD subunit of microsomal triglyceride 
transfer protein most likely explains this debilitating 
disorder. This new observation coincides with the 
recent articulation of a novel hypothesis about the 
subcellular mechanisms by which enterocytes and 
hepatocytes assemble triglyceride-rich particles con- 
taining the large hydrophobic protein apolipoprotein 
B in two steps. In the first step, a small (-200 A), 
apolipoprotein €3-rich microemulsion particle con- 
taining small amounts of triglycerides and cholesteryl 
esters in its core is formed and released into the lumen 
of the rough endoplasmic reticulum. The second step 
requires the synthesis of larger triglyceride-rich par- 
ticles lacking apolipoprotein B in the smooth endo- 
plasmic reticulum. Fusion of these two particles is 
postulated to yield nascent very low density lipopro- 
teins or chylomicrons that can be secreted by hepato- 
cytes and enterocytes, respectively. In classic abetali- 
poproteinemia patients, no apolipoprotein B is found 
in blood plasma, and chylomicrons, very low density 
lipoproteins and low-density lipoproteins are absent. 
The two-step model of triglyceride-rich particle for- 
mation predicts that, in the absence of microsomal 
